Clinical Trials for Cervical Cancer

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic ESCC who have progressed after platinum-based chemotherapy and an immune checkpoint inhibitor are randomized to ifinatamab deruxtecan or investigator’s choice of docetaxel, paclitaxel, or irinotecan. Ifinatamab deruxtecan is an investigational B7-H3–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06644781

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously untreated recurrent, metastatic, or persistent cervical cancer not amenable to curative treatment receive intravenous lorigerlimab, an investigational bispecific antibody that blocks PD-1 and CTLA-4. Eligible patients have measurable disease and ECOG performance status 0–1, with no prior checkpoint inhibitor therapy.

ClinicalTrials.gov ID: NCT05475171

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated, measurable recurrent or progressive gynecologic cancer and a RAS/BRAF pathway alteration receive avutometinib, a dual RAF/MEK inhibitor, plus defactinib, a focal adhesion kinase inhibitor. Low-grade serous ovarian cancer and prior RAF or MEK inhibitor exposure are excluded.

ClinicalTrials.gov ID: NCT05512208

An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: For patients with previously untreated, unresectable recurrent or metastatic HPV16-positive HNSCC with PD-L1 combined positive score ≥1, this trial compares pembrolizumab alone with pembrolizumab plus BNT113. BNT113 is an investigational mRNA vaccine encoding HPV16 E6 and E7 that aims to stimulate tumor-directed T-cell responses.

ClinicalTrials.gov ID: NCT04534205

Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with a qualifying RAS, NF1, RET, NTRK, ALK, or class 2/3 BRAF alteration and either progressive, radioiodine-refractory recurrent/metastatic differentiated thyroid cancer or anaplastic thyroid cancer receive avutometinib plus defactinib. Avutometinib is a RAF/MEK clamp that suppresses ERK signaling; defactinib inhibits FAK/PYK2.

ClinicalTrials.gov ID: NCT06007924

Randomized Phase 2 Clinical Trial of Repeated Intratumoral and Cervical Perilymphatic Lerapolturev Injections Versus Lomustine in Recurrent Glioblastoma (GBM)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent supratentorial glioblastoma suitable for maximal safe resection and a Karnofsky performance status of at least 70 receive either repeated intratumoral lerapolturev followed by cervical perilymphatic injections or oral lomustine. Lerapolturev is a modified poliovirus-based immunotherapy that uses CD155 to enter tumor and immune cells, aiming to injure tumor cells and stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT06177964

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Patients aged ≥10 years with advanced solid tumors or recurrent or progressive primary CNS tumors harboring eligible BRAF fusions or BRAF V600E mutations receive plixorafenib, an oral inhibitor of BRAF V600 signaling and BRAF-containing dimers. Depending on the tumor cohort, plixorafenib is given alone or with cobicistat to increase plixorafenib exposure; patients with metastatic cutaneous melanoma or thyroid cancer are randomized between these regimens.

ClinicalTrials.gov ID: NCT05503797

A Phase II Study of ACR-368 and Low Dose Gemcitabine Combination Therapy in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This single-arm study enrolls patients with measurable recurrent or metastatic head and neck squamous cell carcinoma and ECOG performance status 0–1, generally after PD-1/PD-L1 therapy, in separate p16/HPV-positive and -negative cohorts. Patients receive low-dose gemcitabine plus prexasertib (ACR-368), an investigational CHK1/CHK2 inhibitor that disrupts the response to DNA damage and replication stress.

ClinicalTrials.gov ID: NCT06597565

A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable recurrent or advanced/metastatic hepatocellular, cervical, melanoma, head and neck squamous, platinum-resistant high-grade serous ovarian, or non-small cell lung cancer and ECOG 0–1 receive DB-1311, a B7-H3–targeted topoisomerase I inhibitor antibody–drug conjugate. It is combined with either BNT327, a PD-L1/VEGF-A bispecific antibody, or DB-1305, a TROP2-targeted topoisomerase I inhibitor antibody–drug conjugate.

ClinicalTrials.gov ID: NCT06953089

A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable recurrent or metastatic head and neck squamous cell carcinoma that has progressed after immune checkpoint inhibitor therapy receive oral NRC-2694-A, an investigational EGFR tyrosine kinase inhibitor, plus intravenous paclitaxel. Prior taxane or EGFR-targeted therapy for recurrent or metastatic disease is excluded.

ClinicalTrials.gov ID: NCT05283226